文献速递传染病防控与疫情报告免疫规划卫生政策与健康促进

奥密克戎感染高发期混合免疫的发展

Development of hybrid immunity during a period of high incidence of Omicron infections.
PubMed 文献 · Int J Epidemiol · 2023-01-01

本研究在2022年3月至6/7月对瑞士南部和东北部≥16岁普通人群(南部739人、东北部964人,6/7月补充西部850人随机样本)开展前瞻性、基于人群的多区域队列研究,检测SARS-CoV-2特异性IgG抗体及针对祖先株、德尔塔、奥密克戎的中和抗体。结果显示血清阳性率保持稳定(3月97.6%,6/7月98.4%),6/7月针对奥密克戎的中和能力为84.9%,50.6%产生混合免疫,混合免疫者抗体滴度和中和能力最高。结论认为SARS-CoV-2已成为地方性流行病,支持部分国家仍强烈推荐脆弱人群接种加强针、而普通人群加强接种较少的 emerging 建议。

要点

  • 2022年6/7月,针对奥密克戎的中和能力为84.9%,低于祖先株的94.2%和德尔塔的90.8%。
  • 50.6%的个体产生混合免疫,其抗刺突IgG中位滴度(4518 WHO U/mL)高于仅疫苗(4304 WHO U/mL)或仅感染(269 WHO U/mL)者。
  • 混合免疫者对奥密克戎的中和能力为96.4%,高于仅疫苗的79.5%和仅感染的47.5%。

核心结论

  • SARS-CoV-2已成为地方性流行病,高水平的抗体和中和能力支持部分国家出现的建议,即仍强烈推荐脆弱人群接种加强针,而普通人群加强接种较少。

研究设计与样本

  • 前瞻性、基于人群的多区域队列研究,2022年3月随机选取瑞士南部(n=739)和东北部(n=964)≥16岁普通人群,2022年6/7月再次评估并补充西部随机样本(n=850)。
  • 检测SARS-CoV-2特异性IgG抗体及针对祖先株、德尔塔、奥密克戎的中和抗体。

主要发现

  • 血清阳性率从2022年3月的97.6%(n=1894)稳定至2022年6/7月的98.4%(n=2553)。
  • 2022年6/7月,针对祖先株的中和能力为94.2%,针对德尔塔为90.8%,针对奥密克戎为84.9%,50.6%的个体产生混合免疫。
  • 混合免疫者抗刺突IgG中位滴度为4518 WHO U/mL,仅疫苗诱导免疫者为4304 WHO U/mL,仅感染诱导免疫者为269 WHO U/mL。
  • 混合免疫者对祖先株的中和能力为99.8%(仅疫苗98%,仅感染47.5%),对德尔塔为99%(仅疫苗92.2%,仅感染38.7%),对奥密克戎为96.4%(仅疫苗79.5%,仅感染47.5%)。

临床怎么用

  • 原文结论指出,高水平的抗体和中和能力支持部分国家出现的建议,即仍强烈推荐脆弱人群接种加强针,而普通人群加强接种较少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Seroprevalence and the proportion of people with neutralizing activity (functional immunity) against SARS-CoV-2 variants were high in early 2022. In this prospective, population- based, multi-region cohort study, we assessed the development of functional and hybrid immunity (induced by vaccination and infection) in the general population during this period of high incidence of infections with Omicron variants. METHODS: We randomly selected and assessed individuals aged ≥16 years from the general population in southern (n = 739) and north-eastern (n = 964) Switzerland in March 2022. We assessed them again in June/July 2022, supplemented with a random sample from western (n = 850) Switzerland. We measured SARS-CoV-2 specific IgG antibodies and SARS-CoV-2 neutralizing antibodies against three variants (ancestral strain, Delta, Omicron). RESULTS: Seroprevalence remained stable from March 2022 (97.6%, n = 1894) to June/July 2022 (98.4%, n = 2553). In June/July, the percentage of individuals with neutralizing capacity against ancestral strain was 94.2%, against Delta 90.8% and against Omicron 84.9%, and 50.6% developed hybrid immunity. Individuals with hybrid immunity had highest median levels of anti-spike IgG antibodies titres [4518 World Health Organization units per millilitre (WHO U/mL)] compared with those with only vaccine- (4304 WHO U/mL) or infection- (269 WHO U/mL) induced immunity, and highest neutralization capacity against ancestral strain (hybrid: 99.8%, vaccinated: 98%, infected: 47.5%), Delta (hybrid: 99%, vaccinated: 92.2%, infected: 38.7%) and Omicron (hybrid: 96.4%, vaccinated: 79.5%, infected: 47.5%). CONCLUSIONS: This first study on functional and hybrid immunity in the Swiss general population after Omicron waves showed that SARS-CoV-2 has become endemic. The high levels of antibodies and neutralization support the emerging recommendations of some countries where booster vaccinations are still strongly recommended for vulnerable persons but less so for the general population.

来源:Int J Epidemiol,查看原文。版权归原作者所有。

引用

  1. Frei A, Kaufmann M, Amati R, et al. Development of hybrid immunity during a period of high incidence of Omicron infections. Int J Epidemiol. 2023. PMID: 37407273. doi:10.1093/ije/dyad098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。